What HLA-DR and DQ typing finds
A report may relabel unfamiliar gene codes as susceptible, multisusceptible, or dreaded. That can sound like a diagnosis. The genes cannot show an exposure, an unsafe building, toxins in the body, or the cause of symptoms. Keep the actual alleles and ask what evidence supports the label.
Genes
You inherit two copies at each gene place
The report lists gene versions such as DRB1, DQA1, and DQB1. They do not appear because you entered a building or became ill.
Immune role
HLA proteins show small protein pieces to immune cells
Different gene versions bind different protein pieces. This can support some disease or medicine links, but it does not make every claimed link true.
Report
There is no target range
A gene result is not high, low, optimal, or something to detox. Ask whether a named gene version changes the chance or care of a named condition.
CIRS
The mold code is a separate interpretation
CIRS calculators group gene results into labels. The original gene report is the test result. The susceptibility label needs its own proof.
Genes can't show what building you entered, what you inhaled, whether a substance remains in your body, or why you have thinking problems now. Those questions require their own evidence.
Save this test
Save one lifelong report
My Fog stores the original gene versions and keeps any CIRS label separate, so a calculator summary doesn't replace the genetic result.
Do not repeat to monitor recovery. Repeat only for an incomplete, ambiguous, wrong-resolution, or laboratory-confirmation problem.
How age, pregnancy, privacy, and the test reason affect HLA testing
Your HLA genes do not change with age. The reason for testing, permission, privacy, and meaning can change. A gene version may be common in healthy people and useful only for one clear health question.
Infants and children
Do not label a child mold susceptible from an online calculator without a child-health reason, a talk about permission, and a plan for care. Each parent passes down HLA genes, so the report can reveal family information too.
Teenagers and adults
Ask who'll see the result and why you're having the test. Find out whether it affects a named disease, medicine, or transplant, or only a debated CIRS claim. Keep symptoms and exposure evidence separate from the gene report.
Women, pregnancy, and postpartum
Pregnancy does not change HLA genes. The test may be used for transplant, fertility, immune disease, or another named disease question. A CIRS code does not explain a pregnancy problem. A new severe headache, vision change, trouble breathing, upper-belly pain, or sudden swelling needs pregnancy care now.
Men
Men do not have a separate HLA target range. A mold-susceptible label cannot explain fatigue, thinking trouble, hormone concerns, breathing symptoms, or heart risk. Each problem needs its own check.
Older adults
The genes stay the same. Medicines, sleep disorders, blood-vessel disease, cancer, immune illness, infection, hearing, vision, and brain disease become more likely causes of new thinking changes with age. Do not let an old gene result replace that workup.
How to order and collect the right HLA test
Ask which gene places, called loci, the lab will report and how much detail, called resolution, it will give. A detailed DRB1 transplant test is not the same as a broader DR and DQ disease panel. For DR/DQ questions, the order should name DRB1, DRB3/4/5, DQA1, DQB1, DPA1, and DPB1 if the test includes them.
Mayo's current lower-detail DR/DQ test uses 6 mL of blood in a yellow-top ACD A or B tube. Send the original tube; do not split the blood into another tube. Mayo lists no fasting, morning timing, exercise limit, or medicine change. The report takes 7 to 17 days after the lab receives it.
Labcorp's current detailed DRB1 test is different. It accepts blood in a lavender-top EDTA tube or its own four-swab cheek kit. Keep it at room temperature, protect it from very hot or cold temperatures, and do not freeze it.
Decide where you will store the report before testing. It contains lifelong genetic information. Save the exact lab report. A three-number CIRS code from a calculator or screenshot isn't enough.
Ask what the test is for
Ask whether the test is for transplant matching, a named disease, a serious medicine reaction, or a CIRS claim that is not standard care. The same gene report can be used in very different ways.
Match the loci and resolution
Check whether the order has DRB1 alone or a DR/DQ panel with DQA1 and DQB1. Save whether the report gives low, medium, or high detail and which lab method it used.
Use the laboratory's tube
For Mayo 2DIS, collect 6 mL in a yellow-top ACD tube, keep the blood in the original tube, and do not aliquot. Another laboratory may require EDTA blood or a validated buccal kit.
Read the allele report
Keep both inherited copies for every gene place, all names the lab gives them, and any unclear code. This is not a number with a target range.
Separate genotype from diagnosis
Ask what independent evidence links your gene version to the condition in question, and whether the result changes care. A susceptibility label is not proof of exposure or disease.
How to understand an HLA-DR and DQ report
Start with the gene places, both copies, level of detail, method, and lab comment. Then name the exact health link being checked. Do not let a calculator code replace the original report.
Complete allele report
Alleles reported for the loci ordered
There is no normal or abnormal band. The report names gene versions you inherited. Their meaning depends on the exact health question and the evidence for that gene link.
Incomplete or ambiguous result
Incomplete loci, ambiguous typing, calculator-only code, or missing original report
Treat any missing gene result as unknown. Ask the lab or genetics team whether the genes and level of detail answer the question. An unclear result may need another method.
Allele linked to a named condition
An allele or haplotype associated with a named condition
A gene link changes risk; it does not show whether you have a disease now. Some HLA results can greatly change the chance of a specific disease or medicine reaction. CIRS mold codes have no validated role in diagnosing illness.
The 24% claim does not apply to one person
No study of a large, separate group used to test diagnosis has confirmed the claim that about 24% of people are mold susceptible. HLA genes also differ among populations. The number cannot show whether mold caused your symptoms or whether relatives will become ill.
See research details
The research details keep the lab method, genes, CIRS claims, and building evidence as separate questions.
Preserve the actual allele names and the laboratory comment. A third-party CIRS code is an added interpretation, not the laboratory measurement itself.
Do not turn 24% into a personal probability, a detox defect, or a reason to diagnose relatives. Ask for the source population, allele definitions, exposed comparison group, and independent replication.
Treat the paper as early case evidence. It does not validate a commercial susceptibility calculator or prove that one person's symptoms come from mold.
For any percentage, ask which loci, gene combinations, population registry, ancestry groups, and group size produced it.
Use building evidence for the building question and supported allergy, respiratory, infectious, or other medical assessment for symptoms. A genotype cannot name a building, exposure dose, or safe return date.
What you can do with an HLA report
Food, supplements, detox plans, and habits cannot change an HLA type. Protect the report, check whether evidence supports the label, and deal with symptoms or dampness directly.
Keep the original genetic report
Save every gene place, both copies, all names, level of detail, method, lab, date, and lab comment. A three-number code is not enough to check the result later.
Ask what the result changes
Ask for one sentence that names the health question and one that says what the gene result changes. If the only answer is that you are susceptible, ask what symptom, exposure, or disease evidence is still needed.
Protect genetic privacy
In the US, GINA limits how jobs and health insurers can use genetic information. It does not cover every place or every kind of insurance. Check privacy, permission, and sharing before you upload a full report to a public calculator or forum.
Handle dampness without waiting for genes
If you can see or smell dampness or mold, stop the moisture source, dry wet materials, document damage, and use qualified help when needed. Those actions make sense regardless of HLA type.
Do not move home, test relatives, start binders, antifungals, supplements, prescription treatment, restrictive diets, or major remediation because of an HLA CIRS label alone. Your genes show inherited risk, not current illness. New neurologic deficits, severe breathlessness, chest pain, fainting, or sudden confusion needs direct assessment.
What to save from the genetic report
Keep these together
- Full report, lab, date, sample, method, gene places, and low, medium, or high detail
- Both gene copies for DRB1, DQA1, DQB1, and every other reported gene place, including unclear codes
- Laboratory interpretation, clinical reason for testing, and the independent evidence required for that association
- Any CIRS calculator code as a separate note, with calculator name, version, source, and limits
- Privacy and sharing choice, clinician interpretation, and whether the result changed a real decision
Question for the visit
“Which gene results have a proven link to my health question? What evidence supports any CIRS code? What will change besides the label?”
Sources for HLA-DR Genotype
Current loci, ACD specimen, 6 mL volume, no aliquot, PCR and NGS method, no reference range, interpretation, and 7 to 17 day reporting.
Single-locus high-resolution purpose, NGS, EDTA or buccal specimen, storage, rejection, and test-selection boundary.
Four HLA and mycotoxin case reports and the limits of selected case evidence.
Evidence-based clinical diagnostic boundaries for indoor mold exposure.
Supported medical assessment and treatment boundaries for indoor mold concerns.
Building evidence, absence of health-based indoor mold standards, and moisture correction.
Population and ancestry descriptors, variant-frequency context, and limits of group labels.
US employment protections, confidentiality, and scope of genetic information.
Pregnancy and postpartum warning symptoms requiring direct obstetric care.
See each claim's sources
procedure
Mayo's current low-resolution DR/DQ disease-association test uses PCR and NGS, reports multiple class II loci, and has no numeric reference range.procedure
Mayo 2DIS requires 6 mL whole blood in a yellow-top ACD tube, sent in the original tube without aliquoting, and reports in 7 to 17 days.context
Labcorp's high-resolution DRB1 test is a single-locus NGS test using EDTA whole blood or a validated buccal kit and is not interchangeable with a multi-locus low-resolution DR/DQ panel.limitation
The 2024 direct HLA and mycotoxin paper reported four selected cases and cannot establish population prevalence, diagnostic accuracy, or causal risk by haplotype.limitation
The repeated 24 percent mold-susceptibility claim has not been independently validated as the proportion of people unable to clear mycotoxins or likely to develop CIRS.limitation
HLA-DR/DQ CIRS coding is not an established diagnostic test for indoor mold exposure, a contaminated building, or the cause of brain fog.context
A correctly typed inherited HLA allele result does not change with age, diet, pregnancy, supplements, illness, or treatment.